Repligen Plans NDA for Imaging Agent on Positive Phase III Data

Repligen Corp. reported that its imaging agent RG1068, a synthetic human secretin, showed statistically significant improvements in detecting pancreatic disease via magnetic resonance imaging, and the Waltham, Mass.-based firm plans to meet with the FDA to discuss a new drug application filing.